

Angiolo Gadducci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4504352/publications.pdf>

Version: 2024-02-01

225
papers

8,487
citations

30070

54
h-index

66911

78
g-index

227
all docs

227
docs citations

227
times ranked

7927
citing authors

#	ARTICLE	IF	CITATIONS
1	The management of patients with uterine sarcoma: A debated clinical challenge. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 129-142.	4.4	223
2	Patterns of recurrence in patients with squamous cell carcinoma of the vulva. <i>Cancer</i> , 2000, 89, 116-122.	4.1	215
3	Uterine Leiomyosarcoma: Analysis of Treatment Failures and Survival. <i>Gynecologic Oncology</i> , 1996, 62, 25-32.	1.4	210
4	Endometrial Stromal Sarcoma: Analysis of Treatment Failures and Survival. <i>Gynecologic Oncology</i> , 1996, 63, 247-253.	1.4	183
5	Serum tumor markers in the management of ovarian, endometrial and cervical cancer. <i>Biomedicine and Pharmacotherapy</i> , 2004, 58, 24-38.	5.6	158
6	The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 10-20.	4.4	131
7	Carcinosarcoma of the Uterus: A Clinicopathological Multicenter CTF Study. <i>Gynecologic Oncology</i> , 1997, 67, 70-75.	1.4	126
8	Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Etoposide in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A Randomized Trial of the Gruppo Oncologico Nord-Ovest. <i>Gynecologic Oncology</i> , 2000, 76, 157-162.	1.4	124
9	Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 512-517.	1.4	124
10	Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. <i>Gynecological Endocrinology</i> , 2011, 27, 597-604.	1.7	124
11	Complete Salvage Surgical Cytoreduction Improves Further Survival of Patients with Late Recurrent Ovarian Cancer. <i>Gynecologic Oncology</i> , 2000, 79, 344-349.	1.4	118
12	Management of borderline ovarian tumors: Results of an Italian multicenter study. <i>Gynecologic Oncology</i> , 2006, 101, 255-260.	1.4	117
13	Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1. <i>Journal of Clinical Oncology</i> , 2009, 27, 4642-4648.	1.6	113
14	Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary. <i>British Journal of Cancer</i> , 2013, 109, 29-34.	6.4	113
15	The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis. <i>Gynecologic Oncology</i> , 1992, 44, 147-154.	1.4	110
16	Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 21-31.	2.5	108
17	Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 227-241.	4.4	99
18	Neuroendocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists. <i>Gynecologic Oncology</i> , 2017, 144, 637-646.	1.4	98

#	ARTICLE	IF	CITATIONS
19	Analysis of Treatment Failures and Survival of Patients with Fallopian Tube Carcinoma: A Cooperation Task Force (CTF) Study. <i>Gynecologic Oncology</i> , 2001, 81, 150-159.	1.4	93
20	Treatment options in recurrent cervical cancer (Review). <i>Oncology Letters</i> , 2010, 1, 3-11.	1.8	91
21	Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. <i>Annals of Oncology</i> , 2003, 14, 1086-1093.	1.2	85
22	Polycystic ovary syndrome and gynecological cancers: Is there a link?. <i>Gynecological Endocrinology</i> , 2005, 20, 200-208.	1.7	85
23	Expression and Secretion of Inhibin and Activin in Normal and Neoplastic Uterine Tissues. High Levels of Serum Activin A in Women with Endometrial and Cervical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1194-1200.	3.6	84
24	Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1414-1421.	2.5	84
25	An Analysis of Approaches to the Management of Endometrial Cancer in North America: A CTF Study. <i>Gynecologic Oncology</i> , 1998, 68, 274-279.	1.4	83
26	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. <i>Journal of Ovarian Research</i> , 2019, 12, 9.	3.0	83
27	Analysis of Failures after Negative Second-Look in Patients with Advanced Ovarian Cancer: An Italian Multicenter Study. <i>Gynecologic Oncology</i> , 1998, 68, 150-155.	1.4	81
28	Serum Half-Life of CA 125 during Early Chemotherapy as an Independent Prognostic Variable for Patients with Advanced Epithelial Ovarian Cancer: Results of a Multicentric Italian Study. <i>Gynecologic Oncology</i> , 1995, 58, 42-47.	1.4	80
29	Tissue biomarkers as prognostic variables of cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 104-129.	4.4	80
30	Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). <i>Gynecological Endocrinology</i> , 2017, 33, 39-42.	1.7	79
31	Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study). <i>International Journal of Gynecological Cancer</i> , 2007, 17, 623-628.	2.5	78
32	Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). <i>Gynecologic Oncology</i> , 2010, 119, 48-52.	1.4	78
33	Extra-Nuclear Signaling of Progesterone Receptor to Breast Cancer Cell Movement and Invasion through the Actin Cytoskeleton. <i>PLoS ONE</i> , 2008, 3, e2790.	2.5	75
34	Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 12-27.	4.4	72
35	Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?: A Retrospective Italian Multicentric Study. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 367-374.	2.5	72
36	Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. <i>Anticancer Research</i> , 2003, 23, 5225-9.	1.1	72

#	ARTICLE	IF	CITATIONS
37	Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study. <i>Gynecologic Oncology</i> , 2012, 125, 673-676.	1.4	71
38	Squamous cell carcinoma of the vagina: natural history, treatment modalities and prognostic factors. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 211-224.	4.4	71
39	Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 73-83.	4.4	71
40	Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 242-256.	4.4	70
41	Weekly epirubicin in the treatment of gestational breast cancer (GBC). <i>Breast Cancer Research and Treatment</i> , 2009, 115, 591-594.	2.5	68
42	Is there a role for postoperative treatment in patients with stage Ib2â€“Ib cervical cancer treated with neo-adjuvant chemotherapy and radical surgery? An Italian multicenter retrospective study. <i>Gynecologic Oncology</i> , 2014, 132, 611-617.	1.4	68
43	Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage IIIâ€“IV endometrial cancer patients. <i>Gynecologic Oncology</i> , 2004, 93, 345-352.	1.4	67
44	Surveillance of patients after initial treatment of ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 43-52.	4.4	67
45	Expression and Secretion of Inhibin and Activin in Normal and Neoplastic Uterine Tissues. High Levels of Serum Activin A in Women with Endometrial and Cervical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1194-1200.	3.6	67
46	Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2020, 40, 4819-4828.	1.1	66
47	Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 615-620.	2.5	61
48	Combined Use of CA 125 and CA 15-3 in Patients with Endometrial Carcinoma. <i>Gynecologic Oncology</i> , 1994, 54, 292-297.	1.4	58
49	Pathological response on surgical samples is an independent prognostic variable for patients with Stage Ib2â€“Ib cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: An Italian multicenter retrospective study (CTF Study). <i>Gynecologic Oncology</i> , 2013, 131, 640-644.	1.4	58
50	Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 103-114.	4.4	58
51	Melanoma of the lower genital tract: Prognostic factors and treatment modalities. <i>Gynecologic Oncology</i> , 2018, 150, 180-189.	1.4	57
52	Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis?. <i>Gynecologic Oncology</i> , 2007, 107, S150-S154.	1.4	56
53	Ovarian function and childbearing issues in breast cancer survivors. <i>Gynecological Endocrinology</i> , 2007, 23, 625-631.	1.7	56
54	Surveillance Procedures for Patients Treated for Endometrial Cancer: A Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 985-992.	2.5	55

#	ARTICLE	IF	CITATIONS
55	Pretreatment Plasma Levels of Fibrinopeptide-A (FPA), D-Dimer (DD), and von Willebrand Factor (vWF) in Patients with Ovarian Carcinoma. <i>Gynecologic Oncology</i> , 1994, 53, 352-356.	1.4	54
56	An analysis of approaches to the treatment of endometrial cancer in Western Europe: A CTF study. <i>European Journal of Cancer</i> , 1995, 31, 1993-1997.	2.8	54
57	Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 71-83.	4.4	54
58	Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 153-166.	4.4	53
59	Preoperative Evaluation of D-Dimer and CA 125 Levels in Differentiating Benign from Malignant Ovarian Masses. <i>Gynecologic Oncology</i> , 1996, 60, 197-202.	1.4	51
60	Differential Diagnosis of Adnexal Masses with Transvaginal Sonography, Color Flow Imaging, and Serum CA 125 Assay in Pre- and Postmenopausal Women. <i>Gynecologic Oncology</i> , 1996, 61, 68-72.	1.4	50
61	The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 93, 131-136.	1.4	49
62	Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. <i>Gynecologic Oncology</i> , 2021, 162, 741-750.	1.4	49
63	Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. <i>Anticancer Research</i> , 2009, 29, 1715-20.	1.1	49
64	Correlation of recurrence rates and times with posttreatment human papillomavirus status in patients treated with loop electrosurgical excision procedure conization for cervical squamous intraepithelial lesions. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 90-94.	2.5	47
65	Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. <i>Gynecological Endocrinology</i> , 2014, 30, 612-617.	1.7	47
66	Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 751-758.	1.6	46
67	Uterine smooth muscle tumors of unknown malignant potential: A challenging question. <i>Gynecologic Oncology</i> , 2019, 154, 631-637.	1.4	46
68	Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy. <i>Gynecologic Oncology</i> , 2019, 153, 684-693.	1.4	46
69	The concomitant determination of different serum tumor markers in epithelial ovarian cancer: Relevance for monitoring the response to chemotherapy and follow-up of patients. <i>Gynecologic Oncology</i> , 1992, 44, 155-160.	1.4	45
70	Assessment of the Prognostic Relevance of Serum Anti-p53 Antibodies in Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1999, 72, 76-81.	1.4	45
71	Comparison of the initial surgical experience with robotic and laparoscopic myomectomy. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2014, 10, 208-212.	2.3	45
72	Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2017, 37, 5955-5965.	1.1	45

#	ARTICLE	IF	CITATIONS
73	Gynecological Malignancies in Elderly Patients: Is Age 70 a Limit to Standard-Dose Chemotherapy? An Italian Retrospective Toxicity Multicentric Study. <i>Gynecologic Oncology</i> , 2002, 85, 445-450.	1.4	44
74	The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option. <i>Gynecological Endocrinology</i> , 2009, 25, 683-691.	1.7	44
75	Ovarian Cancer in Elderly Patients: Patterns of Care and Treatment Outcomes According to Age and Modified Frailty Index. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1863-1871.	2.5	44
76	Surgical and Medical Treatment of Clear Cell Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1063-1070.	2.5	43
77	Prognostic factors in uterine sarcoma. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2011, 25, 783-795.	2.8	43
78	Pretreatment Plasma Levels of Fibrinopeptide-A (FPA), D-Dimer (DD), and von Willebrand Factor (vWF) in Patients with Operable Cervical Cancer: Influence of Surgical-Pathological Stage, Tumor Size, Histologic Type, and Lymph Node Status. <i>Gynecologic Oncology</i> , 1993, 49, 354-358.	1.4	42
79	Molecular target therapies in endometrial cancer: From the basic research to the clinic. <i>Gynecological Endocrinology</i> , 2008, 24, 239-249.	1.7	42
80	Serum Levels of Tumor Necrosis Factor (TNF), Soluble Receptors for TNF (55- and 75-kDa sTNFr), and Soluble CD14 (sCD14) in Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1995, 58, 184-188.	1.4	41
81	Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?. <i>Gynecologic Oncology</i> , 2015, 136, 230-234.	1.4	41
82	Clear cell carcinoma of the endometrium: a biological and clinical enigma. <i>Anticancer Research</i> , 2010, 30, 1327-34.	1.1	41
83	Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study. <i>European Journal of Surgical Oncology</i> , 2014, 40, 891-898.	1.0	40
84	Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. <i>Gynecological Endocrinology</i> , 2005, 20, 343-360.	1.7	38
85	Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. <i>Gynecological Endocrinology</i> , 2014, 30, 266-271.	1.7	37
86	PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 153-165.	4.4	37
87	The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: A multicenter retrospective Italian study. <i>Gynecologic Oncology</i> , 2010, 116, 358-363.	1.4	36
88	The Role of HE4 in Ovarian Cancer Follow-up: A Review. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1359-1365.	2.5	36
89	The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 277-282.	2.5	35
90	Adjuvant chemotherapy in stage II uterine leiomyosarcoma: A multicentric retrospective study of 140 patients. <i>Gynecologic Oncology</i> , 2014, 133, 531-536.	1.4	34

#	ARTICLE	IF	CITATIONS
91	Biochemical prognostic factors and risk of relapses in patients with cervical cancer. <i>Gynecologic Oncology</i> , 2007, 107, S23-S26.	1.4	33
92	Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A challenging question for gynecologic oncologists. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 92-98.	4.4	33
93	Could Different Follow-Up Modalities Play a Role in the Diagnosis of Asymptomatic Endometrial Cancer Relapses?: An Italian Multicentric Retrospective Analysis. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1013-1019.	2.5	32
94	Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. <i>Gynecological Endocrinology</i> , 2010, 26, 568-577.	1.7	31
95	Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. <i>International Journal of Gynecological Cancer</i> . 2017, 27, 28-36.	2.5	31
96	Intraperitoneal Carboplatin with or without Interferon- γ in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients. <i>Gynecologic Oncology</i> , 1997, 65, 499-505.	1.4	30
97	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	4.6	30
98	P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. <i>Anticancer Research</i> , 2006, 26, 687-93.	1.1	30
99	Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. <i>European Journal of Cancer</i> , 1994, 30, 1432-1435.	2.8	29
100	Up date in the management of advanced ovarian carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 49-58.	4.4	29
101	Controversial issues in climacteric medicine II. <i>Maturitas</i> , 2001, 40, 117-130.	2.4	29
102	Surveillance Procedures for Patients With Cervical Carcinoma: A Review of the Literature. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 194-201.	2.5	29
103	The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 126-140.	4.4	29
104	Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. <i>Cancer</i> , 2007, 109, 645-649.	4.1	28
105	Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 113-128.	4.4	28
106	Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research. <i>Cancers</i> , 2020, 12, 1336.	3.7	27
107	Human Telomerase Reverse Transcriptase mRNA Expression Assessed by Real-Time Reverse Transcription Polymerase Chain Reaction Predicts Chemosensitivity in Patients With Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 1320-1325.	1.6	26
108	Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 943-953.	2.5	25

#	ARTICLE	IF	CITATIONS
109	Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. <i>Anticancer Research</i> , 2003, 23, 549-56.	1.1	24
110	Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. <i>Anticancer Research</i> , 2011, 31, 3483-8.	1.1	24
111	Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. <i>Anticancer Research</i> , 2003, 23, 3001-8.	1.1	23
112	Current management of fallopian tube carcinoma. <i>Current Opinion in Obstetrics and Gynecology</i> , 2002, 14, 27-32.	2.0	22
113	Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue. <i>Gynecological Endocrinology</i> , 2009, 25, 807-815.	1.7	22
114	Multimodality approach in extra cervical locally advanced cervical cancer: Chemoradiation, surgery and intra-operative radiation therapy. A phase II trial. <i>European Journal of Surgical Oncology</i> , 2011, 37, 442-447.	1.0	22
115	Pretreatment platelet and hemoglobin levels are neither predictive nor prognostic variables for patients with locally advanced cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy: a retrospective Italian study. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1399-404.	2.5	22
116	Second-line treatment and consolidation therapies in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 52-56.	2.5	21
117	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Società Italiana di Ginecologia e Obstetrica). <i>Journal of Gynecological Oncology</i> , 2008, 18, 107-114.	2.8	21
118	Serum Macrophage Colony-Stimulating Factor (M-CSF) Levels in Patients with Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1998, 70, 111-114.	1.4	20
119	First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients. <i>Gynecologic Oncology</i> , 2003, 89, 354-359.	1.4	20
120	An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 792-800.	2.5	20
121	Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours. <i>Gynecological Endocrinology</i> , 2014, 30, 467-471.	1.7	20
122	Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9). <i>Oncology</i> , 2014, 86, 351-358.	1.9	20
123	Acute and late vaginal toxicity after adjuvant high-dose-rate vaginal brachytherapy in patients with intermediate risk endometrial cancer: is local therapy with hyaluronic acid of clinical benefit?. <i>Journal of Contemporary Brachytherapy</i> , 2016, 6, 512-517.	0.9	20
124	Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. <i>Gynecological Endocrinology</i> , 2004, 19, 216-228.	1.7	19
125	Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer: An Italian Multicenter Retrospective Study. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 461-468.	2.5	19
126	Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 181-192.	4.4	18

#	ARTICLE	IF	CITATIONS
127	Fertility drug use and risk of ovarian tumors: a debated clinical challenge. <i>Gynecological Endocrinology</i> , 2013, 29, 30-35.	1.7	18
128	Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemoradiotherapy in Cervical Cancer: a Preliminary Analysis. <i>Anticancer Research</i> , 2017, 37, 1249-1256.	1.1	18
129	Elevated Serum Levels of Neopterin and Soluble Interleukin-2 Receptor in Patients with Ovarian Cancer. <i>Gynecologic Oncology</i> , 1994, 52, 386-391.	1.4	17
130	Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 27-34.	4.4	17
131	Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy. <i>Gynecological Endocrinology</i> , 2013, 29, 25-29.	1.7	17
132	Adjuvant treatment and analysis of failures in patients with high-risk FIGO Stage I b—II endometrial cancer: An Italian multicenter retrospective study (CTF study). <i>Gynecologic Oncology</i> , 2014, 134, 29-35.	1.4	17
133	Definitive Radiotherapy for Primary Squamous Cell Carcinoma of the Vagina: Are High-Dose External Beam Radiotherapy and High-Dose-Rate Brachytherapy Boost the Best Treatment? Experience of Two Italian Institutes. <i>Oncology Research and Treatment</i> , 2017, 40, 697-701.	1.2	17
134	Locally advanced squamous cell carcinoma of the vulva: A challenging question for gynecologic oncologists. <i>Gynecologic Oncology</i> , 2020, 158, 208-217.	1.4	17
135	Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. <i>Anticancer Research</i> , 2007, 27, 4403-9.	1.1	17
136	Preoperative D-Dimer Plasma Assay Is Not a Predictor of Clinical Outcome for Patients with Advanced Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 66, 85-88.	1.4	16
137	Follow-up strategies in gynecological oncology: searching appropriateness. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 1186-1193.	2.5	16
138	Concomitant External-beam Irradiation and Chemotherapy Followed by High-dose Rate Brachytherapy Boost in the Treatment of Squamous Cell Carcinoma of the Vagina: A Single-Center Retrospective Study. <i>Anticancer Research</i> , 2016, 36, 1885-9.	1.1	16
139	PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2016, 36, 2055-64.	1.1	16
140	Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma. <i>Gynecologic Oncology</i> , 1987, 28, 278-283.	1.4	15
141	Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. <i>International Journal of Gynecological Cancer</i> , 1997, 7, 78-83.	2.5	15
142	Survival after intestinal obstruction in patients with fatal ovarian cancer: Analysis of prognostic variables. <i>International Journal of Gynecological Cancer</i> , 1998, 8, 177-182.	2.5	15
143	Alternatives to risk-reducing surgery for ovarian cancer. <i>Annals of Oncology</i> , 2013, 24, viii47-viii53.	1.2	15
144	Reproductive outcomes after hydatiform mole and gestational trophoblastic neoplasia. <i>Gynecological Endocrinology</i> , 2015, 31, 673-678.	1.7	15

#	ARTICLE	IF	CITATIONS
145	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	6.4	15
146	Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. <i>Anticancer Research</i> , 2006, 26, 3925-32.	1.1	15
147	Prothrombin Fragment F1+2 and Thrombin Antithrombin III Complex (TAT) Plasma Levels in Patients with Gynecological Cancer. <i>Gynecologic Oncology</i> , 1996, 61, 215-217.	1.4	14
148	The Relationship between Postoperative Decline of Serum CA 125 Levels and Size of Residual Disease after Initial Surgery in Patients with Advanced Ovarian Cancer: A CTF Study. <i>Gynecologic Oncology</i> , 1996, 63, 234-237.	1.4	14
149	Weekly Low-Dose Paclitaxel as Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Had Microscopic Residual Disease at Second-Look Surgery After 6 Cycles of Paclitaxel/Platinum-Based Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 615-619.	2.5	14
150	The evolving role of adjuvant therapy in endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 79-91.	4.4	14
151	Clinical Outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study. <i>Anticancer Research</i> , 2019, 39, 2513-2517.	1.1	14
152	Adenoid Cystic Carcinoma of Bartholin's Gland: What Is the Best Approach?. <i>Oncology</i> , 2020, 98, 513-519.	1.9	14
153	Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. <i>Anticancer Research</i> , 2005, 25, 2509-13.	1.1	14
154	Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. <i>Anticancer Research</i> , 2010, 30, 201-8.	1.1	14
155	Malignant Transformation in Mature Cystic Teratomas of the Ovary: Case Reports and Review of the Literature. <i>Anticancer Research</i> , 2018, 38, 3669-3675.	1.1	13
156	Endometrial Cancer: When Upfront Surgery Is Not an Option. <i>Oncology</i> , 2021, 99, 65-71.	1.9	13
157	Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 1996, 6, 286-290.	2.5	12
158	New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications. <i>Gynecological Endocrinology</i> , 2012, 28, 582-586.	1.7	12
159	Analysis of Treatment Failures and Survival of Patients With Uterine Papillary Serous Carcinoma: A Cooperation Task Force (CTF) Study. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1355-1360.	2.5	12
160	Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. <i>Journal of Ovarian Research</i> , 2014, 7, 72.	3.0	12
161	Pharmacological treatment for uterine leiomyosarcomas. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 335-346.	1.8	12
162	Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2016, 29, 489-495.	0.7	12

#	ARTICLE	IF	CITATIONS
163	Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist. <i>Anticancer Research</i> , 2020, 40, 2429-2438.	1.1	12
164	Is Perineural Invasion a Novel Prognostic Factor Useful to Tailor Adjuvant Treatment in Patients Treated With Primary Surgery for Cervical and Vulvar Carcinoma?. <i>Anticancer Research</i> , 2020, 40, 3031-3037.	1.1	12
165	Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 1031-44.	2.3	12
166	The treatment of progressive ovarian carcinoma with D-Trp-LHRH (decapeptyl). <i>European Journal of Cancer</i> , 1994, 30, 1903-1904.	2.8	11
167	Prognostic role of immunosuppressive acidic protein in advanced ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 175, 1606-1610.	1.3	11
168	Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study. <i>Gynecologic Oncology</i> , 2018, 151, 449-452.	1.4	11
169	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016, 11, e0149872.	2.5	11
170	Renal impairment in patients with ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2003, 106, 198-202.	1.1	10
171	Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. <i>Gynecological Endocrinology</i> , 2013, 29, 811-816.	1.7	10
172	Perivascular epithelioid cell tumors (PEComa) of the female genital tract: A challenging question for gynaecologic oncologist and pathologist. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100603.	0.6	10
173	Serum Soluble Interleukin-2 Receptor Assay in Epithelial Ovarian Cancer. <i>Tumor Biology</i> , 1993, 14, 303-309.	1.8	9
174	Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix â€” An Italian Multicenter Retrospective Study. <i>Anticancer Research</i> , 2018, 38, 3627-3634.	1.1	9
175	Definitive radiotherapy for recurrent vulvar carcinoma after primary surgery: a two-institutional Italian experience. <i>Tumori</i> , 2019, 105, 225-230.	1.1	9
176	Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. <i>Anticancer Research</i> , 2016, 36, 3477-82.	1.1	9
177	Comparison of Tumor-Associated Trypsin Inhibitor (Tati) with Ca125 as a Marker for Diagnosis and Monitoring of Epithelial Ovarian Cancer. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1991, 51, 19-24.	1.2	8
178	Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1134-1140.	2.5	8
179	A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab. <i>BMC Urology</i> , 2019, 19, 128.	1.4	8
180	Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research. <i>Cancers</i> , 2020, 12, 2678.	3.7	8

#	ARTICLE	IF	CITATIONS
181	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). <i>Tumori</i> , 2021, 107, 100-109.	1.1	8
182	The Prognostic Relevance of Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Gynecological Cancer. <i>Anticancer Research</i> , 2021, 41, 9-20.	1.1	8
183	MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach. <i>Tumori</i> , 2022, 108, 376-385.	1.1	8
184	Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review. <i>Anticancer Research</i> , 2021, 41, 4673-4685.	1.1	8
185	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 145-152.	1.2	8
186	Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study. <i>Anticancer Research</i> , 2022, 42, 2017-2022.	1.1	8
187	Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study. <i>Gynecologic Oncology</i> , 2005, 98, 118-123.	1.4	7
188	Comparison between single-site and multiport robot-assisted hysterectomy in obese patients with endometrial cancer: An Italian multi-institutional study. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2020, 16, e2066.	2.3	7
189	Analysis of failures in patients with FIGO stage IIIc1-IIIc2 endometrial cancer. <i>Anticancer Research</i> , 2012, 32, 201-5.	1.1	7
190	Adjuvant Radiotherapy in High-Risk Squamous Cell Carcinoma of the Vulva: A Two-Institutional Italian Experience. <i>Oncology Research and Treatment</i> , 2017, 40, 778-783.	1.2	6
191	Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study. <i>Anticancer Research</i> , 2020, 40, 2191-2197.	1.1	6
192	Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study. <i>Anticancer Research</i> , 2018, 38, 1695-1703.	1.1	6
193	Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach. <i>Anticancer Research</i> , 2010, 30, 3731-5.	1.1	6
194	Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy. <i>Oncology</i> , 2019, 96, 235-241.	1.9	5
195	Pregnancy-associated cancers: frequency and temporal trends in Italy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 241-244.	2.5	5
196	Dose-dense Neoadjuvant Chemotherapy With Paclitaxel and Carboplatin in Cervical Cancer: Efficacy on Pathological Response. <i>Anticancer Research</i> , 2021, 41, 497-502.	1.1	5
197	Molecular Characterization of Peritoneal Involvement in Primary Colon and Ovary Neoplasm: The Possible Clinical Meaning of the P2X7 Receptor-Inflammasome Complex. <i>European Surgical Research</i> , 2022, 63, 114-122.	1.3	5
198	Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue. <i>Anticancer Research</i> , 2020, 40, 5995-6002.	1.1	5

#	ARTICLE	IF	CITATIONS
199	Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma. <i>Anticancer Research</i> , 2015, 35, 1099-104.	1.1	5
200	Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer". <i>Cancers</i> , 2021, 13, 6155.	3.7	5
201	Evolving Role of Serum Biomarkers in the Management of Ovarian Cancer. <i>Women's Health</i> , 2006, 2, 141-158.	1.5	4
202	Dose Individualization Can Minimize Nephrotoxicity due to Carboplatin Therapy in Patients With Ovarian Cancer. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 63-69.	2.0	4
203	Post-traumatic Stress Disorder in patients with ovarian cancer. <i>International Review of Psychiatry</i> , 2017, 29, 403-408.	2.8	4
204	Perineural Invasion Correlates With Common Pathological Variables and Clinical Outcomes of Patients With Squamous Cell Carcinoma of the Vulva Treated With Primary Radical Surgery and Inguinal-femoral Lymphadenectomy. <i>In Vivo</i> , 2021, 35, 1051-1056.	1.3	4
205	Adjuvant chemotherapy in early-stage endometrioid endometrial cancer with >50% myometrial invasion and negative lymph nodes. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 537-544.	2.5	4
206	The management of malignant nondysgerminomatous ovarian germ cell tumors. <i>Anticancer Research</i> , 2003, 23, 1827-36.	1.1	4
207	Analysis of the Evolution in the Management of Endometrial Cancer in Italy: A CTF Study. <i>Tumori</i> , 2002, 88, 481-488.	1.1	3
208	Angiosarcoma after adjuvant radiotherapy in high-risk squamous cell carcinoma of the vulva: a case report. <i>Przegląd Menopauzalny</i> , 2019, 18, 230-234.	1.3	3
209	PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5613-TPS5613.	1.6	3
210	Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study. <i>Anticancer Research</i> , 2022, 42, 947-954.	1.1	3
211	The role of the French-Italian glossary of complications in the outcome evaluation of cervical cancer treatment: an Italian multicentric study. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 317-321.	4.4	2
212	Fertility outcome of breast cancer and Hodgkin's lymphoma female survivors: a growing clinical challenge for gynecologists and oncologists. <i>Gynecological Endocrinology</i> , 2013, 29, 729-734.	1.7	2
213	"Batlike" choroid plexus and other sonographic features in trisomy 22 at the first trimester of pregnancy. <i>Prenatal Diagnosis</i> , 2013, 33, 1013-1014.	2.3	2
214	Have Volume-based Parameters of Positron Emission Tomography/Computed Tomography Prognostic Relevance for Patients With Potentially Platinum-responsive Recurrent Ovarian Cancer? A Single Center Italian Study. <i>Anticancer Research</i> , 2021, 41, 1937-1944.	1.1	2
215	Combined Evaluation of Serum CA 125 and CAM 29 in Patients with Epithelial Ovarian Cancer. <i>Tumor Biology</i> , 1992, 13, 287-293.	1.8	1
216	Prevention of Cis-Platinum Nephrotoxicity in a High-Risk Patient. <i>Renal Failure</i> , 1996, 18, 691-695.	2.1	1

#	ARTICLE	IF	CITATIONS
217	Ovarian cancer in elderly women. <i>International Journal of Gynecological Cancer</i> , 1997, 7, 23-26.	2.5	1
218	Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 225-238.	2.4	1
219	Unilateral adnexal agenesis and dermoid cyst: fertility implications. <i>Gynecological Endocrinology</i> , 2015, 31, 438-440.	1.7	1
220	Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study. <i>Anticancer Research</i> , 2020, 40, 1543-1550.	1.1	1
221	A narrative review of pregnancy after malignancies in young women that donâ€™t originate in the female genital organs or in the breast. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103240.	4.4	1
222	The Role of Skin Tests in the Prevention and Diagnosis of Hypersensitivity Reactions to Platinum Agents in Gynecological Cancer: A Single-Center Italian Retrospective Study. <i>Cancers</i> , 2021, 13, 5468.	3.7	1
223	Radiotherapy as Definitive Treatment of Patients with Primary Vulvar Carcinoma Unfit for Surgery and with Recurrent Vulvar Carcinoma After Primary Radical Surgery: Results of a Retrospective Single-center Study. <i>Anticancer Research</i> , 2016, 36, 387-91.	1.1	1
224	Is reduction in size pathognomonic of functional ovarian cysts?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2003, 21, 622-624.	1.7	0
225	Primary Perivascular Epithelioid Cell Tumor (PEComa) of the Ovary: A Case Report and Review of the Literature. <i>Anticancer Research</i> , 2021, 41, 4483-4488.	1.1	0